Date and Time:  Thursday 24th October 2013, 09.30 – 16.30

Minutes:

Guideline Development Group Meeting
Place:   NCGC Boardroom, Great Portland Street, London

Present:
  Philip Conaghan (Chair)
  Mark Porcheret (MP)
  Ian Bernstein (IB)
  Fraser Birrell (FB)
  Michael Doherty (MD)
  Rob Middleton (RM)
  Krysia Dziedzic (KD)
  Weiya Zhang (WZ)
  Erika Baker (EB)
  Brian Lucas (BL)
  Peter Kay (PK)
  Elspeth Wise (EW)
  Jo Cumming (JC)
  Richard Frearson (RF)

  Sue Latchem, Guideline Lead and Operations Director (SL)
  Emmert Roberts, Research Fellow (ER)
  Margaret Constanti, Health Economist (MC)
  Fiona Rooney, Project Manager (FR)
  Nancy Pursey, Senior Project Manager (NP)
  Dave Wonderling, Head of Health Economics (DW) (Present for items 1-5)

In attendance:

<table>
<thead>
<tr>
<th>NICE Staff:</th>
<th>Observers:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Doak (BD)</td>
<td>None for this meeting</td>
</tr>
<tr>
<td>Lyn Knott (LK)</td>
<td>(Present for items 3-4)</td>
</tr>
<tr>
<td>Denise Woods (DW)</td>
<td></td>
</tr>
<tr>
<td>Mark Baker (MB)</td>
<td></td>
</tr>
</tbody>
</table>

Apologies:

Tony Whiting (TW)
Notes
1. The Chair welcomed the group to the twelfth meeting of this GDG. Apologies were received from TW. The Chair asked all GDG members to declare any relevant conflicts of interest.

Declarations of Interest

**PC (chair)**
Declared a personal pecuniary interest:
Will participate in an advisory board to develop a new NSAID in November 2013 for Infirst.

**IB**
Declared personal pecuniary interests:
Course organiser and lecturer at a musculoskeletal education workshop in October 2013. The meeting was organised by NHS Ealing CCG and sponsored by Pfizer. Payment of £600 for organising the course was received from NHS Ealing CCG. Speaker at the British Institute of Musculoskeletal Medicine annual symposium in December. Honorarium of £100 and travel expenses paid.

Declared a non-personal pecuniary interest:
Lecturer at the Association for Medical Osteopathy presenting the draft OA guidelines and discussing the LETR. Will not receive payment or hospitality.

**WZ**
Declared a personal pecuniary interest:
Invited speaker for the 2nd World Congress on Controversies, Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD) taking place November 21-24, 2013 in Brussels Belgium. Travel and expenses paid.

**FB**
Declared personal pecuniary interests:

**KD**
Declared personal pecuniary interests:
Gave a presentation on the NICE 2008 OA guideline and the NICE draft OA guideline while in consultation to Rheumatology Registrars. No payment received.
Gave a presentation at the AGILE physiotherapy conference on the 2008 OA guideline. Accommodation and food paid. No expenses received or fees paid.

**EW**
Declared a personal non-pecuniary interest:
BMJ Masterclass in Manchester in September 2013.

**JC**
Declared personal pecuniary interests:
Participated in media event for DePuy hip joints and prosthetics. Received £600 honorarium paid directly to Arthritis Care
Attendance fee for Bone and Muscle Joint Disease Congress sponsored by Abbvie to enable a poster presentation to be submitted. Received £490 for BMJD registration paid directly to Arthritis Care

**MD**
Declared a personal non-pecuniary interest:
Wrote a review ‘Mechanisms of the placebo response in pain in OA’ for a special issue on pain
Notes
in Osteoarthritis and Cartilage 2013;21:1229-35. Received no payment or hospitality.
Speaker at Ono to discuss a novel drug for pain in OA. Received no payment or hospitality.
Speaker at conference in Liverpool in October 2013 to discuss rare diseases in cartilage, not OA related. Received no payment or hospitality.

No other interests were declared.

No further actions were taken following these declarations other than those outlined.

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

3. An update was given to the GDG on progress since the last meeting.

4. The Chair introduced MB, the Director at the Centre for Clinical Practice at NICE, who gave a short presentation on the issues raised by stakeholder comments during the consultation phase particularly in relation to pharmacological management. The GDG discussed the issues presented. The Chair thanked MB for his attendance and MB then left the meeting.

5. The GDG discussed stakeholder comments raised during the consultation and considered how to respond to these.

6. ER presented an additional paper for the review on Hyaluronans. There was no change to the recommendations.

7. The Chair introduced DW, from the implementations directorate at NICE. DW explained that NICE will carry out an implementation needs assessment.

8. SL suggested the GDG may need to meet one more time dependent upon NICE discussions on next steps. All agreed. Date to be potentially arranged in January 2014.

9. The Chair asked the GDG whether there were any items under AOB and closed the meeting at 17:00.

Date, time and venue of the next meeting
To be confirmed as required. (post meeting note: further meeting not convened)